Advanced Accelerator Applications SA - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Advanced Accelerator Applications SA (AAA), a Novartis company, is engaged in developing, producing and commercializing diagnostic and therapeutic molecular nuclear medicine products. The companys lead product candidate comprises Lutathera, NETSPOT, SOMAKIT TOC, Gluscan, Gluscan 500, Barnascan, Fluorochol, AAACholine, Cholscan, MIBITEC, Adamibi, Leukokit, Neurolite and Lumark. AAA develops new medicines which targets the orphan diseases in the field of cardiology, oncology, neurology and inflammation. It is also engaged in manufacturing Positron Emission tomography (PET) and single-photon emission computed tomography (SPECT). The company operates in France, Italy, the UK, Germany, Switzerland, Spain, Poland, Portugal, Israel, the US, and Canada, among others. AAA is headquartered in Saint-Genis-Pouilly, Auvergne, France.

Advanced Accelerator Applications SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

it derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.



List of Tables 5
List of Figures 5
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Advanced Accelerator Applications SA, Medical Devices Deals, 2012 to YTD 2018 10
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Advanced Accelerator Applications Raises USD26 Million in Venture Financing 13
Advanced Accelerator Applications Raises US$56 Million In Venture Financing 14
Advanced Accelerator Raises US$6 Million In First Tranche Of Venture Financing 15
Partnerships 16
Advanced Accelerator Applications Enters into Agreement with National Cancer Institute 16
Vect-Horus Enters into Collaboration Agreement with Advanced Accelerator Applications for Radio-Imaging Agents 17
Licensing Agreements 18
Advanced Accelerator Enters into Licensing Agreement with Cancer Targeted Technology 18
Advanced Accelerator Applications Enters into Licensing Agreement with Erasmus University Medical Center and Demokritos National Center 19
Advanced Accelerator Applications Enters into Licensing Agreement with Johns Hopkins University 20
Fujifilm RI Pharma Enters into Licensing Agreement with Advanced Accelerator Applications 21
Equity Offering 22
Advanced Accelerator Applications Prices Public Offering of American Depositary Shares for USD172.5 Million 22
Advanced Accelerator Applications to Raise up to USD80 Million in IPO 24
Acquisition 26
Novartis Acquires Advanced Accelerator Applications for USD3.9 Billion 26
Advanced Accelerator Applications Acquires IDB Group 28
Advanced Accelerator Applications Acquires Remaining 49.9% Stake in Atreus Pharma 29
Advanced Accelerator Applications SA - Key Competitors 30
Advanced Accelerator Applications SA - Key Employees 31
Advanced Accelerator Applications SA - Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 34
Financial Announcements 34
Nov 17, 2017: Advanced Accelerator Applications Reports 39% Sales Growth for Third Quarter 2017 34
Aug 31, 2017: Advanced Accelerator Applications Reports 32% Sales Growth for Second Quarter 2017 35
May 31, 2017: Advanced Accelerator Applications Reports 21% Sales Growth for First Quarter 2017 37
Mar 23, 2017: Advanced Accelerator Applications Reports 23% Sales Growth for Fiscal 2016; Continued NETSPOT Launch Success 39
Corporate Communications 41
May 25, 2017: Advanced Accelerator Applications Appoints Christine Mikail to Board of Directors 41
Product News 42
09/29/2017: Advanced Accelerator Applications Announces European Approval of Lutetium (177Lu) Oxodotreotide (Lutathera) for Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors 42
07/28/2017: EMA Recommends Granting a Marketing Authorisation for Lutetium (177Lu) Oxodotreotide 43
07/21/2017: Advanced Accelerator Applications Announces Positive CHMP Opinion Recommending Approval of Lutetium 177Lu Oxodotreotide (Lutathera) for Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors 44
03/21/2018: Lenox Hill successfully treats esthesioneuroblastoma with PRRT 45
01/26/2018: Lutathera Drug Approved for Pancreatic Neuroendocrine Tumors 46
01/26/2018: Advanced Accelerator Applications Receives FDA Approval for Lutathera for Treatment of Gastroenteropancreatic Neuroendocrine Tumors 47
Product Approvals 48
Aug 28, 2017: Advanced Accelerator Applications Announces New Prescription Drug User Fee Act date of January 26, 2018, for Lutetium Lu 177 Dotatate (Lutathera) 48
Jul 27, 2017: Advanced Accelerator Applications Completes Resubmission of NDA for Lutetium Lu 177 Dotatate (Lutathera) to FDA 49
Jan 09, 2017: Advanced Accelerator Applications CEO Provides Progress Report on Corporate Developments of 2016; Asserts Confidence in Ability to Address FDA Comments on Lutathera NDA 50
Clinical Trials 52
Jun 12, 2018: Newly-Approved Therapy Provides Improved Quality of Life for Patients with Advanced Metastatic Midgut Neuroendocrine Tumors 52
Jun 07, 2018: Novartis announces JCO publication of Lutathera NETTER-1 data showing significantly longer time to deterioration of key quality of life measures in patients with progressive midgut NETs 53
Feb 21, 2018: New Cancer Treatment for Neuroendocrine Tumors 54
Sep 06, 2017: Advanced Accelerator Applications Announce First Patient in Bridging Study in Japan for Lutetium Lu 177 Dotatate (Lutathera) 55
Jun 12, 2017: Targeted Radionuclide Treatment for Neuroendocrine Tumors Improves Quality of Life 56
Mar 06, 2017: Advanced Accelerator Applications Announces Presentation of Quality of Life Findings from NETTER-1 Phase III Study at ENETS 57
Jan 12, 2017: Advanced Accelerator Applications Announces New England Journal of Medicine Publication of Lutathera NETTER-1 Phase III Results 58
Jan 12, 2017: New drug in development shows improved survival for patients with advanced metastat 59
Other Significant Developments 60
Jan 09, 2017: Advanced Accelerator Applications CEO Provides Progress Report on Corporate Developments of 2016; Asserts Confidence in Ability to Address FDA Comments on Lutathera NDA 60
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List Of Tables


Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Key Facts 2
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Advanced Accelerator Applications SA, Deals By Therapy Area, 2012 to YTD 2018 9
Advanced Accelerator Applications SA, Medical Devices Deals, 2012 to YTD 2018 10
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Advanced Accelerator Applications Raises USD26 Million in Venture Financing 13
Advanced Accelerator Applications Raises US$56 Million In Venture Financing 14
Advanced Accelerator Raises US$6 Million In First Tranche Of Venture Financing 15
Advanced Accelerator Applications Enters into Agreement with National Cancer Institute 16
Vect-Horus Enters into Collaboration Agreement with Advanced Accelerator Applications for Radio-Imaging Agents 17
Advanced Accelerator Enters into Licensing Agreement with Cancer Targeted Technology 18
Advanced Accelerator Applications Enters into Licensing Agreement with Erasmus University Medical Center and Demokritos National Center 19
Advanced Accelerator Applications Enters into Licensing Agreement with Johns Hopkins University 20
Fujifilm RI Pharma Enters into Licensing Agreement with Advanced Accelerator Applications 21
Advanced Accelerator Applications Prices Public Offering of American Depositary Shares for USD172.5 Million 22
Advanced Accelerator Applications to Raise up to USD80 Million in IPO 24
Novartis Acquires Advanced Accelerator Applications for USD3.9 Billion 26
Advanced Accelerator Applications Acquires IDB Group 28
Advanced Accelerator Applications Acquires Remaining 49.9% Stake in Atreus Pharma 29
Advanced Accelerator Applications SA, Key Competitors 30
Advanced Accelerator Applications SA, Key Employees 31
Advanced Accelerator Applications SA, Subsidiaries 32

List Of Figures


Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Advanced Accelerator Applications SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Advanced Accelerator Applications SA, Medical Devices Deals, 2012 to YTD 2018 10

Advanced Accelerator Applications SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Advanced Accelerator Applications SA (AAA), a Novartis company, is engaged in developing, producing and commercializing diagnostic and therapeutic molecular nuclear medicine products. The companys lead product candidate comprises Lutathera, NETSPOT,

USD 250 View Report

Advanced Accelerator Applications SA - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Advanced Accelerator Applications SA (AAA), a Novartis company, is engaged in developing, producing and commercializing diagnostic and therapeutic molecular nuclear medicine products. The companys lead product candidate comprises Lutathera, NETSPOT,

USD 250 View Report

Advanced Accelerator Applications SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Advanced Accelerator Applications SA (AAA), a Novartis company, is engaged in developing, producing and commercializing diagnostic and therapeutic molecular nuclear medicine products. The companys lead product candidate comprises Lutathera, NETSPOT,

USD 250 View Report

Advanced Accelerator Applications SA - Medical Equipment - Deals and Alliances Profile

Advanced Accelerator Applications SA (AAA), a Novartis company, is engaged in developing, producing and commercializing diagnostic and therapeutic molecular nuclear medicine products. The companys lead product candidate comprises Lutathera, NETSPOT,

USD 250 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available